Why Hire CNP Holders Rigorous designation criteria ensure CNP-designated professionals will be superior contributors to an organization's bottom-line. Customers are assured of high-quality network systems being used to develop and support products and services.
The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.
The US Food and Drug Administration (FDA) approved a new formulation of buprenorphine, allowing patients to visit their provider once a month for an injection to treat opioid use disorder.